Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 12, 2012, Pages

  Colmers, Isabelle N ^a   Bowker, Samantha L ^a   Majumdar, Sumit R ^a   Johnson, Jeffrey A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HIGH RISK PATIENT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 84865858873     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.112102     Document Type: Article

References (31)

1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
2. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23.
3. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602.
4. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31.
5. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011;18:R125-47.
6. Kakehi Y, Hirao Y, Kim W-J, et al. Bladder Cancer Working Group report. Jpn J Clin Oncol 2010;40(Suppl 1):i57-64.
7. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.
8. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI. Paris (France): Caisse National d'Assurance Maladie; 2011. Available: www.afssaps.fr/var/afssaps-site/storage/ original/application/b42a6bf9a1b63c3dbec7388d3914687b.pdf (accessed 2012 June 6).
9. Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-71.
10. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22.
11. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011;54:2009-15.
12. Higgins JPT, Altman DG, Sterne JAC, editors. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available: www.cochrane-handbook.org (accessed 2012 June 6).
13. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available: www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 2012 June 6).
14. Reeves BC, Deeks JJ, Higgins JPT, et al. Including non-randomized studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available: www.cochrane-handbook.org (accessed 2012 June 6).
15. Sterne JAC, Egger M, Moher D, editors. Addressing reporting biases. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available: www.cochrane-handbook.org (accessed 2012 June 6).
16. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
17. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
18. Oliveria SA, Koro C, Ulcickas Yood M, et al. Cancer incidence among patients treated with antidiabetic therapy. Diabetes Metab Syndr 2009;2:45-57.
19. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55:1953-62. Mar. 31 [Epub ahead of print].
20. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80.
21. Insulin glargine injection treatment in place of thiazolidinedione (TZD), sulfonylurea, or metformin in triple agent therapy for type 2 diabetes mellitus (T2DM) subjects with unsatisfactory control [trial registration no. NCT00283049]. ClinicalTrials.gov. Available: http://clinicaltrials.gov/ct2/show/ NCT00283049 (accessed 2012 June 6).
22. Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53:1838-45.
23. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004;27:982-91.
24. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009;8:6-15.
25. Lubet RA, Fischer SM, Steele VE, et al. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitro - samine-induced urinary bladder cancers. Int J Cancer 2008;123:2254-9.
26. Actos (pioglitazone hydrochloride): full prescribing information. Deerfield (IL): Takeda Pharmaceuticals America; 2012. Available: http://general.takedapharm.com/content/file/pi.pdf?applicationcode= 8a9c4571-a123-4477-91de-b9cafe7d07e3&filetypecode=actospi (accessed 2012 June 6).
27. Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer [letter]. Lancet 2011;378:1543-4.
28. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer [press release]. London (UK): European Medicines Agency; 2011. Available: www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/10/ WC500116936.pdf (accessed 2012 June 6).
29. Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer. Ottawa (ON): Health Canada; 2011. Available: www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2011/2011-79-eng.php (accessed 2012 June 6).
30. FDA Drug Safety Communication. Updated drug labels for pioglitazone-containing medicines. Silver Spring (MD): Food and Drug Administration; 2011. Available: www.fda.gov/Drugs/DrugSafety/ucm266555.htm (accessed 2012 June 6).
31. Johnson JA, Carstensen B, Witte D, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 2012;55:1607-18.